Dai 2006.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 80. Age: aripiprazole group: 24～58 years, mean = 31 years; risperidone group: not reported. Gender: aripiprazole group: 28 male, 12 female; risperidone group: 24 male, 16 female. History: aripiprazole group: 1 month～8 years, mean = 6.4 years; risperidone group: not reported. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐20 mg/day. Mean dose: not reported. N = 40. 2. Risperidone: Dose range: 5‐20 mg/day. Mean dose: not reported. N = 40.
Outcomes	Global state: PANSS score decreased rate (markedly improved: ≥70%, improved: 40%‐70%, no effect: < 40%). Mental state: PANSS total score. Adverse effects
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	Low risk	No selective reporting.
Other bias	Low risk	None obvious.